Free tool
FAERS Monitor: Secuado
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212268 or its brand name (Secuado, Asenapine). Reports on generic versions are filed under their own applications.
Reports
912
Serious
722
79% of reports
Hospitalization
337
Death reported
139
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective115
- drug interaction87
- off label use74
- completed suicide73
- toxicity to various agents67
- myocarditis58
- sedation40
- depression36
- somnolence32
- suicidal ideation32
- product substitution issue31
- weight increased31
- anxiety29
- hypotension28
- insomnia28
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 11 |
| 2011 | 18 |
| 2012 | 20 |
| 2013 | 19 |
| 2014 | 66 |
| 2015 | 93 |
| 2016 | 88 |
| 2017 | 52 |
| 2018 | 28 |
| 2019 | 47 |
| 2020 | 45 |
| 2021 | 74 |
| 2022 | 101 |
| 2023 | 62 |
| 2024 | 49 |
| 2025 | 89 |
| 2026 | 50 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,247 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myocarditisSignal | 58 | 117.3 | 91.4 | 6,542 |
| sedationSignal | 40 | 35.3 | 26.0 | 1,298 |
| completed suicideSignal | 73 | 20.2 | 16.2 | 1,319 |
| drug interactionSignal | 87 | 12.7 | 10.4 | 929 |
| product substitution issueSignal | 31 | 12.4 | 8.8 | 315 |
| toxicity to various agentsSignal | 67 | 9.2 | 7.3 | 483 |
| suicidal ideationSignal | 32 | 8.1 | 5.7 | 192 |
| somnolenceSignal | 32 | 3.7 | 2.6 | 60 |
| depressionSignal | 36 | 3.6 | 2.6 | 67 |
| hypotensionSignal | 28 | 3.2 | 2.2 | 41 |
| weight increasedSignal | 31 | 3.2 | 2.3 | 45 |
| insomniaSignal | 28 | 2.4 | 1.7 | 22 |
| anxietySignal | 29 | 2.4 | 1.6 | 21 |
| drug ineffectiveSignal | 115 | 2.0 | 1.7 | 61 |
| off label use | 74 | 1.9 | 1.6 | 35 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.